SecBot SecBot
424B5 ·Filed Jun 3, 2026

CELC

Celcuity Inc.
BEARISH
Impact 6/10
Horizondays Processed5mo ago SEC0001493152-26-026972
Notable filing: 424B5
Actionable Insight ▼ Bearish

The $400M convertible note offering adds significant leverage and future dilution risk. Monitor the final conversion price and interest rate in the priced prospectus supplement. The debt-for-debt swap (secured to unsecured) improves balance sheet flexibility but at the cost of higher total debt. Watch for potential stock price pressure from convertible arbitrage hedging by note purchasers.

DirectionBearish
Confidencemedium
Horizondays

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$88.95
T+0 close · Jun 3, 2026 · via day close
Latest settled
+4.82%
T+60 · $93.24
Vs SPY
+2.32%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 3 $88.95entry
  2. T+1 · 6mo ago +3.96%α +3.56% · $92.47
  3. T+5 · 5mo ago −0.80%α +3.02% · $88.24
  4. T+20 · 5mo ago +21.36%α +22.36% · $107.95
  5. T+60 · 3mo ago +4.82%α +2.32% · $93.24
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Celcuity is offering $400M in convertible senior notes due 2032 (with a $60M over-allotment option). Proceeds will repay $137.9M in secured term loans under the A&R Loan Agreement, with the remainder for working capital and general corporate purposes including clinical trials and commercial launch. The filing is preliminary with placeholder interest rate and conversion price, but the $400M size and debt-for-debt swap (secured to unsecured) are material.

Key Facts

  • $400M aggregate principal amount of convertible senior notes due 2032 (up to $460M with over-allotment)
  • Proceeds to repay $137.9M in secured term loans under the A&R Loan Agreement (as of March 31, 2026)
  • Total long-term debt would increase from $339.1M to $601.3M pro forma (as of March 31, 2026)
  • Notes are unsecured senior obligations, ranking equal with existing $201.25M 2.750% Convertible Senior Notes due 2031
  • Conversion price and interest rate are placeholders (TBD in final prospectus supplement)
  • Stock price on June 2, 2026: $91.42 per share
  • Underwriters include Jefferies, J.P. Morgan, TD Cowen, Guggenheim Securities, LifeSci Capital, Craig-Hallum, Wolfe | Nomura Alliance

Financial Impact

$400M debt issuance increases total long-term debt from $339.1M to $601.3M (77% increase); $137.9M secured debt eliminated, replaced by unsecured convertible notes

debtdilutioninterest expenseleverage

Risk Factors

  • Dilution from potential conversion of notes into common stock (conversion price TBD but likely at a premium to current $91.42 stock price)
  • Increased interest expense from $400M in new debt; cash interest payments will reduce cash runway
  • Stock price decline risk from convertible arbitrage short selling by note investors
  • No established trading market for the notes; liquidity risk for noteholders
  • Pro forma leverage increases significantly; may constrain future financing flexibility

Market Snapshot

Exchange
Nasdaq
Sector
Services-Medical Laboratories
Analyst Consensus
94% bullish (18 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
424B5 Filing (Primary)0001493152-26-026972
Document: 0001493152-26-026972-index-headers.html0001493152-26-026972
Document: 0001493152-26-026972-index.html0001493152-26-026972
Document: 0001493152-26-026972.txt0001493152-26-026972

Track record

26 reports on CELC

Performance horizon

6 of 12 bullish or bearish reports moved the stock their way by T+5. Best: +26.84% at T+20 after the Jun 11, 2026 report. 8 of 12 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $62.58 Now $60.57 −3.21% settles Nov 23
  2. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $64.37 Now $60.57 −5.90% settles Nov 23
  3. Nov 9, 20267d ago Press Release Bullish 5/10 Entry $70.37 to $60.57 Now $60.57 −13.93% ▼ −13.93% −12.23% vs SPY
  4. Nov 5, 202611d ago 8-K Neutral 5/10 No price data
  5. Nov 5, 202611d ago Press Release Neutral 5/10 Entry $66.79 to $64.37 Now $60.57 −9.31% ▼ −3.62% −6.22% vs SPY
  6. Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $69.72 to $67.05 Now $60.57 −13.12% ▼ −3.83% −3.24% vs SPY
  7. Oct 24, 202623d ago Press Release Bullish 6/10 Entry $65.80 to $69.13 Now $60.57 −7.95% ▲ +5.06% +6.32% vs SPY
  8. Oct 5, 20266w ago 3 Neutral 2/10 Entry $71.25 to $63.19 Now $60.57 −14.99% ▼ −11.31% −11.17% vs SPY
  9. Oct 2, 20266w ago 8-K Neutral 2/10 Entry $72.10 to $67.94 Now $60.57 −15.99% ▼ −5.77% −6.93% vs SPY
  10. Sep 30, 20266w ago 8-K Bullish 6/10 Entry $79.52 to $65.78 Now $60.57 −23.83% ▼ −17.28% −19.19% vs SPY
Showing 10 of 26

US Market Status

Market Closed · Opens in 8h 27m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 3, 2026